Small Molecules - Big Game!

Key Takeaways

• Small molecules maintain critical market presence with five positions in the top ten oncology drugs by sales revenue globally in 2022 , demonstrating sustained commercial viability despite biologics growth
• The "pill penalty" devastated small molecule investment with aggregate investments by companies under $2 billion dropping 68% since the Inflation Reduction Act , as small molecules face price negotiations after just 9 years versus 13 years for biologics
• Breakthrough targeting technologies unlock "undruggable" proteins through PROTACs and molecular glues that selectively degrade target proteins rather than inhibit them, achieving more profound and durable therapeutic effects
• Economic pressures favor small molecule manufacturing with Structure Therapeutics' 6,000 ton capacity supplying 120+ million patients annually while biologics face complex manufacturing with material costs at 30% of total project costs
• Market resurgence is accelerating with small molecules projected to reach $1,281.7 billion by 2029 at 5.0% CAGR and potential regulatory reform eliminating the pill penalty through equal 13-year negotiation timelines

Will the future of innovation be driven by small molecules or will biologics still lead the way -We try to explore all possibilities in this research piece!

The Foundation: Understanding Small Molecules

• The defining advantage of small molecules lies in their compact molecular architecture, typically ranging from 1.5 to 2.0 kDa in molecular weight, significantly smaller than biologics which can exceed 150 kDa
• This size differential enables cell membrane permeability and access to intracellular targets that remain inaccessible to larger therapeutic modalities.
• Small molecules possess optimizable physicochemical properties that can be systematically modified through synthetic chemistry

The structural simplicity of small molecules compared to biologics enables precise chemical modifications during development, allowing researchers to fine-tune properties for specific therapeutic applications while maintaining manufacturing feasibility

• Small molecules demonstrate remarkable mechanistic versatility, engaging biological targets through enzyme inhibition, receptor modulation, and protein-protein interaction disruption
• Recent innovations have dramatically expanded small molecule capabilities - Proteolysis-targeting chimeras (PROTACs) and molecular glues enable small molecules to selectively degrade target proteins rather than simply inhibiting them. This catalytic mode of action allows a single molecule to eliminate multiple copies of disease-causing proteins, achieving more profound and durable therapeutic effects than traditional inhibition.

The ability to target intracellular proteins represents a fundamental advantage, as approximately 75% of human proteins remain "undruggable" by traditional approaches. Small molecules can readily cross cell membranes to access these targets, including transcription factors, scaffolding proteins, and enzyme modulators that lack accessible binding pockets for larger therapeutic modalities.

• Advanced small molecule platforms now enable targeting of G-protein coupled receptors (GPCRs) with biologic-like activity and specificity while maintaining the advantages of oral administration. These developments represent significant progress toward addressing previously intractable targets
• Small molecules offer substantial manufacturing scalability through established synthetic chemistry processes, contrasting sharply with the complex biological systems required for biologics production.

Cost-effectiveness stems from several factors: well-established synthetic procedures, multiple potential suppliers, and simplified quality control compared to biologics. The fully synthetic manufacturing process eliminates dependence on living cell systems, reducing production complexity and costs while ensuring supply chain reliability

• Storage and distribution advantages include room temperature stability for most small molecules, eliminating the cold chain requirements often necessary for biologics. This reduces logistical costs and improves accessibility, particularly in resource-limited settings.
• Oral bioavailability represents the most significant clinical advantage of small molecules, offering patient convenience, improved compliance, and reduced healthcare system burden. This route of administration enables patient self-management and eliminates the need for healthcare provider administration required by most biologics.
• Small molecules demonstrate superior tissue distribution capabilities due to their low molecular weight and optimizable properties, enabling systemic distribution with the ability to penetrate specialized tissues including the central nervous system. Compounds with TPSA less than 60 Ų can achieve blood-brain barrier penetration, expanding therapeutic applications to neurological conditions.
• These foundational advantages - chemical versatility, manufacturing efficiency, clinical convenience, and intracellular targeting capability - establish small molecules as indispensable tools in pharmaceutical development, providing the scientific rationale for their continued prominence in addressing unmet medical needs across diverse therapeutic areas

Small molecules with Big Success Stories

Eliquis (Apixaban) - The Anticoagulant Champion

• Eliquis, developed jointly by Bristol Myers Squibb and Pfizer, generated $20.7 billion in global sales in 2024, making it the second-highest selling drug worldwide - This direct oral anticoagulant has revolutionized stroke prevention in atrial fibrillation and treatment of venous thromboembolism.
• The drug's success stems from its superior safety profile compared to warfarin, requiring no routine monitoring and offering more predictable pharmacokinetics. Eliquis captured approximately 40% of the direct oral anticoagulant market in the United States by 2023.
• Biktarvy - The HIV Treatment Revolution

Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)

• Manufactured by Gilead Sciences, achieved $13.4 billion in sales in 2024, this single-tablet regimen has transformed HIV treatment by combining three active ingredients into one daily pill
• The drug's success is attributed to its excellent tolerability profile and high barrier to resistance

Jardiance Family - The Diabetes and Heart Failure Game-Changer

• The Jardiance family of drugs (empagliflozin-based treatments), co-developed by Boehringer Ingelheim and Eli Lilly, generated $13.0 billion in combined sales in 2024 - This SGLT2 inhibitor has expanded beyond diabetes treatment to include heart failure and chronic kidney disease indications.
• Jardiance has generated over $26.8 billion in total sales since its launch in 2014. The drug's success was catalyzed by landmark clinical trials demonstrating cardiovascular benefits, including a 38% reduction in cardiovascular death and 35% reduction in hospitalization for heart failure

Ibrance (Palbociclib) - The Precision Oncology Pioneer

• Ibrance, Pfizer's CDK4/6 inhibitor for breast cancer, achieved approximately $4.8 billion in global sales in 2023, though facing some market pressures from newer competitors. The drug revolutionized treatment for hormone receptor-positive, HER2-negative advanced breast cancer

Lipitor (Atorvastatin) - The All-Time Revenue Champion

• Lipitor represents perhaps the most successful small molecule drug in pharmaceutical history, generating over $125 billion in lifetime sales for Pfizer. At its peak in 2006, the cholesterol-lowering statin achieved $12.9 billion in annual sales
• Even after patent expiration in 2011, Lipitor continues to generate approximately $2 billion annually for Pfizer, primarily from emerging markets like China. The drug's longevity demonstrates the enduring value of well-designed small molecules that address large patient populations with chronic conditions. Lipitor is projected to remain among the top three pharmaceutical products by lifetime sales through 2028

Strategic Insights from Blockbuster Success

These five case studies reveal several critical success factors for small molecule blockbusters: superior drug design focusing on safety and efficacy profiles, strategic lifecycle management through indication expansion, first-mover advantages in novel mechanism categories, oral bioavailability benefits for chronic conditions, and platform development approaches that maximize therapeutic applications across related diseases

These successes demonstrate that despite competitive pressures from biologics, thoughtfully designed small molecules continue to achieve blockbuster status and generate substantial returns for pharmaceutical companies

Change of Market Dynamics: The Introduction of the Pill Penalty

Regulatory Impact on Small Molecule Development

• The "pill penalty" provisions of the Inflation Reduction Act (IRA) represent one of the most significant policy challenges facing small molecule drug development

Under this legislation, small molecule drugs become eligible for Medicare price negotiations after just 9 years, compared to 13 years for biologics. This four-year difference has created a substantial disincentive for small molecule innovation

• The policy implications are stark: pharmaceutical companies report a 70% drop in small molecule drug investment since the IRA provisions were initially drafted in September 2021. Additionally, 78% of pharmaceutical companies indicate they expect to cancel early-stage small molecule pipeline projects due to reduced return on investment potential
• PhRMA's analysis indicates that small molecules may be selected just 7 years after FDA approval for price negotiations, with government-set prices taking effect 2 years later, creating a practical commercial window of only 9 years compared to 13 years for biologics. This timeline compression occurs earlier than they would otherwise face generic or biosimilar competition, fundamentally disrupting traditional pharmaceutical economics

This "pill penalty" provision has fundamentally altered investment incentives, creating a regulatory framework that systematically disadvantages small molecule development and threatens the pipeline of oral medications that form the backbone of accessible healthcare

• The pill penalty particularly impacts the most profitable years of a drug's lifecycle -Typically, 40% of a drug's total revenue is generated between years 10-14, precisely the period that small molecules would lose under the current policy structure

Did Pill Penalty Actually kill the Small Molecule Market?

Innovation and Development Consequences

• The pill penalty particularly impacts post-approval research and development. PhRMA's research shows that more than 60% of small molecule cancer medicines approved a decade ago received additional indications in later years, and nearly half of those occurred 7 or more years after initial approval. The compressed timeline especially jeopardizes the development of these critical treatments and the post-approval R&D that is necessary to realize their full therapeutic potential

Companies face increased strategic constraints given that companies only have a seven-year commercial window from your first launch, forcing them to develop multiple indications simultaneously, which means additional cost and increased risk since you haven't necessarily proven concept yet. This fundamentally alters clinical development strategies and resource allocation decisions

The policy creates perverse incentives favoring biologics over small molecules

The pill penalty incentivizes large molecule development and technically causes drug prices to increase overall, since small molecules have an inherent discount level compared to large molecules because even if they're priced the same, you don't have administration cost issues

Strategic Industry Responses

• Pharmaceutical companies have pivoted toward therapeutic areas exempt from IRA negotiations
• Large pharma companies are shifting their portfolios towards rare disease, orphan disease programs, mainly because they are exempt from negotiations

Companies are also adjusting development timelines and indication strategies to maximize value within compressed commercial windows, fundamentally altering how pharmaceutical innovation is prioritized and funded

Reform Advocacy and Political Momentum

The pharmaceutical industry has mobilized significant advocacy efforts to address the disparity

Vital Transformation advocates for the Ensuring Pathways to Innovative Cures (EPIC) Act, which would align small molecule drugs with biologics under a 13-year timeline - Their modeling suggests that removing the "pill penalty" by beginning IRA price setting for both drug types after 13 years would increase FDA approvals targeting the Medicare-aged population by 21%.

• PhRMA has prioritized rectifying the disparate treatment of small molecule medicines under the IRA by aligning the price setting timeline with biologics. Leveling the years impacted to be consistent between the two represents the number one priority for the trade association.
• Political momentum appears to be building, with an AstraZeneca expert noting that the White House has already said they will look for ways to take on that pill penalty. However, implementation challenges remain, as the Inflation Reduction Act was part of a larger reconciliation omnibus bill, raising questions about what vehicle will be utilized to create those changes

The Renaissance: Factors Driving Small Molecule Comeback

• After decades of biologics dominance in pharmaceutical innovation, small molecule drugs are experiencing a remarkable renaissance driven by breakthrough technologies, economic pressures, and a clearer understanding of biologics limitations

• This resurgence represents more than just a cyclical shift, it reflects fundamental advances in drug discovery, manufacturing capabilities, and therapeutic approaches that are reshaping the pharmaceutical landscape and positioning small molecules as the backbone of accessible, scalable healthcare solutions

AI-Driven Drug Discovery Revolution

• Artificial intelligence has emerged as the most transformative force revitalizing small molecule development, enabling researchers to navigate vast chemical spaces with unprecedented precision and speed

Novel Targeting Mechanisms: Protein Degradation and Molecular Glues

• The development of targeted protein degradation (TPD) technologies, particularly PROTACs and molecular glues, has unlocked previously "undruggable" proteins and expanded the therapeutic potential of small molecules beyond traditional inhibition approaches

Biologics Limitations Driving Market Correction

• The pharmaceutical industry is increasingly recognizing the inherent limitations of biologics that create opportunities for small molecule alternatives
• Multiple industry experts emphasize that biologics manufacturing is complex, highly regulated, and subject to multiple risks, with costs generally higher than traditional small molecule chemical compounds and manufacturing processes less reliable and more difficult to reproduce
• Biopharma supply chain analysis reveals that biologics face intrinsically complex supply chains with material costs representing roughly 30% of total costs for typical projects

Investment and Funding Patterns

• Venture capital funding in biopharma rebounded strongly in 2024 with over 20% year-on-year investment growth, breaking a two-year downward trend. Importantly, seed rounds increased to 40% of all deals as investors look toward early-stage opportunities, suggesting renewed confidence in fundamental drug discovery.

• The trend toward "fewer but larger" deals with mega-rounds exceeding $100 million indicates that successful small molecule companies will have access to substantial capital for development. This funding environment, combined with reduced development costs through AI and improved success rates, creates favorable conditions for small molecule innovation

The renaissance of small molecules represents a fundamental shift driven by technological innovation, economic realities, and a maturing understanding of therapeutic modalities. As AI continues to expand the druggable universe, novel mechanisms unlock previously inaccessible targets, and delivery technologies enhance bioavailability, small molecules are positioned to reclaim their central role in pharmaceutical innovation while addressing the global need for accessible, scalable healthcare solutions

Conclusion: The Path Forward

The small molecule pharmaceutical sector stands at a critical inflection point, where regulatory challenges meet unprecedented technological opportunities. Despite the significant impact of the IRA's pill penalty, which resulted in a 68-70% drop in small molecule R&D investment, multiple indicators point toward a strategic comeback driven by innovation, investor adaptation, and market fundamentals.

Key success factors for the small molecule renaissance include:

• Technological Innovation: AI-powered drug discovery, novel modalities like PROTACs, and advanced screening technologies are expanding what's possible with small molecules
• Strategic Investment: Major pharmaceutical companies' $200+ billion investment commitments demonstrate continued confidence in the sector's long-term potential
• Market Position: Small molecules' 64% share of 2024 FDA approvals and 58% global market share reflect enduring clinical and commercial relevance
• Investment Recovery: Early signs of VC re-engagement and strategic partnership formation suggest the worst of the downturn may be stabilizing

Intelligience Opnion:

Future Outlook: The Evolving Landscape of Small Molecule Innovation

The pharmaceutical industry stands at an inflection point where small molecules are poised to reclaim their position as drivers of therapeutic innovation. As we look toward the next decade, several converging forces suggest a fundamental transformation in how small molecule drugs are discovered, developed, and positioned within the broader therapeutic landscape.

Small molecules are here to stay and both Big pharma and smart investors know this and have learnt to work their way

• The investment community is beginning to differentiate between broad sector concerns and specific high-quality opportunities. While some investors remain cautious about Medicare-exposed indications, others are finding attractive opportunities in orphan diseases, novel technologies, and international markets.

Looking ahead, the small molecule sector's recovery will likely depend on three critical factors: continued technological innovation that expands therapeutic possibilities, potential policy adjustments that address the pill penalty, and sustained investor confidence in the fundamental advantages of small molecule therapeutics

• The data strongly suggests that investors are indeed beginning to invest again in small molecules, albeit with more sophisticated risk assessment and mitigation strategies. This selective re-engagement, combined with robust market fundamentals and unprecedented technological capabilities, positions small molecules for a sustained comeback that could define the next decade of pharmaceutical innovation

• The pill penalty, however has been able to curtail small molecules growth - The policy represents a fundamental policy misstep that has already begun reshaping pharmaceutical innovation in ways that may ultimately harm patient access to affordable oral medications, and unless there are meaningful reform to align small molecule and biologics timelines, the continued shift away from small molecule development threatens decades of progress in accessible healthcare delivery
• The renaissance of small molecules is not just about returning to past successes, it represents a fundamental evolution in how these versatile compounds can address humanity's most pressing health challenges through the integration of cutting-edge science, strategic investment, and policy-aware development approaches.

Disclaimer: The information provided in this content does not constitute financial, legal, investment, or professional advice of any kind. The content is based on publicly available information, industry trends, and hypothetical scenarios and reflects the author’s interpretation of such data and is is purely speculative and for informational purposes only. No representation or warranty, express or implied, is made as to the accuracy, completeness, or reliability of the information presented.

The author, publisher, and any affiliated parties expressly disclaim any and all liability for any direct, indirect, incidental, consequential, or special damages arising from or in connection with the use of or reliance on this content, including but not limited to financial losses, legal disputes, regulatory actions, or other adverse outcomes. Readers are solely responsible for their own investment, financial, legal, or other decisions and should not rely on this content as a basis for such decisions. Before making any investment or business decisions, readers are strongly advised to consult with qualified financial advisors, legal counsel, or other professionals to assess the risks, suitability, and implications of any actions.

The author and publisher are not affiliated with any of the companies discussed and have no financial interest in the outcomes of the speculated acquisitions. Any mention of stock performance, market valuations, or financial metrics is illustrative and not intended to influence market behavior. Readers acknowledge that investing in securities involves significant risks, including the potential loss of principal, and that past performance is not indicative of future results.

By accessing or using this content, readers agree to hold harmless the author, publisher, and any affiliated parties from any claims, damages, or liabilities arising from its use, interpretation, or dissemination. This disclaimer applies to all forms of liability, including but not limited to negligence, breach of contract, tort, or statutory violations, to the fullest extent permitted by law.

This article represents a fact-based research piece and is not in any manner a guidance document or represents an exhaustive review and is open to inputs from industry experts and a dialogue that will spark meaningful conversations. Examples quoted in this article are not exhaustive but representative of the context.

Few excerpts have been derived from paid financial analysts' report and may not be available for free distribution. In case of any missed or incorrect hyperlinks or incorrect data, please message!

The author represents a CI firm called Intelligience. Please DM her for a detailed discussion around the evolving CI landscape in Biopharma!

Copyright Intelligience 2025 -All rights reserved